ATE238052T1 - Susstituierte alkanhydroxamisaeure und verfahren zur verminderung des tnf-alphaspiegels - Google Patents

Susstituierte alkanhydroxamisaeure und verfahren zur verminderung des tnf-alphaspiegels

Info

Publication number
ATE238052T1
ATE238052T1 AT98938151T AT98938151T ATE238052T1 AT E238052 T1 ATE238052 T1 AT E238052T1 AT 98938151 T AT98938151 T AT 98938151T AT 98938151 T AT98938151 T AT 98938151T AT E238052 T1 ATE238052 T1 AT E238052T1
Authority
AT
Austria
Prior art keywords
hydroxamic acids
substituted alkane
alpha levels
reducing tnf
levels
Prior art date
Application number
AT98938151T
Other languages
English (en)
Inventor
George W Muller
Hon-Wah Man
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Application granted granted Critical
Publication of ATE238052T1 publication Critical patent/ATE238052T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/62—Naphtho [c] pyrroles; Hydrogenated naphtho [c] pyrroles
    • C07D209/66—Naphtho [c] pyrroles; Hydrogenated naphtho [c] pyrroles with oxygen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Materials Applied To Surfaces To Minimize Adherence Of Mist Or Water (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
AT98938151T 1997-07-31 1998-07-30 Susstituierte alkanhydroxamisaeure und verfahren zur verminderung des tnf-alphaspiegels ATE238052T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90397597A 1997-07-31 1997-07-31
PCT/US1998/015868 WO1999006041A1 (en) 1997-07-31 1998-07-30 SUBSTITUTED ALKANOHYDROXAMIC ACIDS AND METHOD OF REDUCING TNFα LEVELS

Publications (1)

Publication Number Publication Date
ATE238052T1 true ATE238052T1 (de) 2003-05-15

Family

ID=25418328

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98938151T ATE238052T1 (de) 1997-07-31 1998-07-30 Susstituierte alkanhydroxamisaeure und verfahren zur verminderung des tnf-alphaspiegels

Country Status (20)

Country Link
US (3) US6214857B1 (de)
EP (1) EP1035848B1 (de)
JP (1) JP2001511448A (de)
KR (1) KR100716475B1 (de)
CN (1) CN1265590A (de)
AT (1) ATE238052T1 (de)
AU (1) AU737008B2 (de)
BR (1) BR9815895A (de)
CA (1) CA2295295A1 (de)
CZ (1) CZ299873B6 (de)
DE (1) DE69813876T2 (de)
ES (1) ES2196592T3 (de)
FI (1) FI119841B (de)
HU (1) HUP0003761A3 (de)
NO (1) NO315043B1 (de)
NZ (1) NZ502379A (de)
PT (1) PT1035848E (de)
RU (1) RU2199530C2 (de)
TR (1) TR200000221T2 (de)
WO (1) WO1999006041A1 (de)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429221B1 (en) 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US6518281B2 (en) * 1995-08-29 2003-02-11 Celgene Corporation Immunotherapeutic agents
FI990180A7 (fi) 1996-08-12 1999-03-08 Celgene Corp Uusia immunoterapeuttisia aineita ja niiden käyttö sytokiini-tasojen pienentämiseksi
ES2196592T3 (es) * 1997-07-31 2003-12-16 Celgene Corp Acidos alcanohidroxamicos sustituidos y metodo para reducir el nivel de tnf-alfa.
AU2594799A (en) 1998-02-11 1999-08-30 Du Pont Pharmaceuticals Company Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US6667316B1 (en) * 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US6699899B1 (en) * 1999-12-21 2004-03-02 Celgene Corporation Substituted acylhydroxamic acids and method of reducing TNFα levels
US8030343B2 (en) * 2000-06-08 2011-10-04 Celgene Corporation Pharmaceutically active isoindoline derivatives
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
TR201809678T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
CN1658848A (zh) 2002-04-12 2005-08-24 细胞基因公司 血管生成调节剂的鉴定方法,由此发现的化合物和使用该化合物的治疗方法
US20100129363A1 (en) * 2002-05-17 2010-05-27 Zeldis Jerome B Methods and compositions using pde4 inhibitors for the treatment and management of cancers
EP1556033A4 (de) * 2002-05-17 2006-05-31 Celgene Corp Verfahren und zusammensetzungen mit selektiven cytokin-hemmenden arzneimitteln zur behandlung und versorgung von krebs und anderen erkrankungen
WO2004014365A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Phthalimide derivatives as matrix metalloproteinase inhibitors
MXPA05003889A (es) * 2002-10-15 2005-06-22 Celgene Corp Farmacos inhibidores de citosina selectiva para tratar sindrome mielodisplastico.
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040087558A1 (en) 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US7776907B2 (en) * 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
MXPA05004486A (es) * 2002-10-31 2005-07-26 Celgene Corp Metodo de uso y composiciones que comprenden farmacos inhibidores de citocina, selectivos, para el tratamiento y el manejo de la degeneracion macular.
BR0316002A (pt) * 2002-11-06 2005-09-13 Celgene Corp Métodos de tratar ou prevenir e controlar uma doença mieloproliferativa, de reduzir ou evitar de um efeito adverso associado com a administração de um segundo agente ativo em um paciente sofrendo de uma doença mieloproliferativa e de aumentar a eficácia terapêutica de um tratamento de doença mieloproliferativa, composição farmacêutica e kit
WO2004043378A2 (en) * 2002-11-06 2004-05-27 Celgene Corporation Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
KR20050075435A (ko) * 2002-11-18 2005-07-20 셀진 코포레이션 (＋)-３-(３,４-디메톡시-페닐)-３-(１-옥소-１,３-디히드로-이소인돌-２-일)-프로피온아미드의 사용 방법 및 그를포함하는 조성물
CA2506442A1 (en) * 2002-11-18 2004-07-01 Celgene Corporation Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
KR20050090435A (ko) 2002-12-30 2005-09-13 셀진 코포레이션 플루오로알콕시-치환된 1,3-디히드로-이소인돌릴 화합물 및그의 제약학적 용도
ZA200507322B (en) * 2003-03-06 2007-03-28 Celgene Corp Selective cytokine inhibitory drugs for treating disorders of the central nervous system
US20040175382A1 (en) * 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
NZ542670A (en) * 2003-03-12 2008-11-28 Celgene Corp N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses
BRPI0408223A (pt) 2003-03-12 2006-03-01 Celgene Corp composto, isÈmeros, composição farmacêutica, e, métodos de inibir pde4 e mmp, de modular a produção de tnf-alfa em um mamìfero e de tratar, previnir ou controlar uma doença ou condição
CN100427465C (zh) * 2003-03-12 2008-10-22 细胞基因公司 N-烷基-异羟肟酸-异吲哚基化合物及其药物用途
US7320992B2 (en) 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
DE10340739A1 (de) * 2003-09-04 2005-04-07 Satia Gmbh Verfahren zur enzymatischen Herstellung von Mono- und Diacylglycerid-haltigen Emulgatoren
CA2543132A1 (en) * 2003-10-23 2005-05-19 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US20050142104A1 (en) * 2003-11-06 2005-06-30 Zeldis Jerome B. Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders
US20080213213A1 (en) * 2004-04-14 2008-09-04 Zeldis Jerome B Method For the Treatment of Myelodysplastic Syndromes Using (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione
CA2563377A1 (en) * 2004-04-23 2005-11-03 Celgene Corporation Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension
CN1984652A (zh) * 2004-05-05 2007-06-20 细胞基因公司 使用选择性细胞因子抑制药治疗和控制骨髓增生性疾病的方法和组合物
CN1984651A (zh) * 2004-05-05 2007-06-20 细胞基因公司 使用选择性细胞因子抑制药治疗和控制癌症和其它疾病的方法和组合物
US7405237B2 (en) * 2004-07-28 2008-07-29 Celgene Corporation Isoindoline compounds and methods of their use
TW200613272A (en) * 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
US20070190070A1 (en) * 2004-09-03 2007-08-16 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
EP1811992A2 (de) * 2004-10-28 2007-08-01 Celgene Corporation Verfahren und zusammensetzungen unter verwendung von pde4-modulatoren zur behandlung und versorgung von verletzungen des zentralen nervensystems
US20080138295A1 (en) * 2005-09-12 2008-06-12 Celgene Coporation Bechet's disease using cyclopropyl-N-carboxamide
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
CA2659412A1 (en) 2006-07-31 2008-02-07 Janssen Pharmaceutica N.V. Urotensin ii receptor antagonists
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
PA8782701A1 (es) * 2007-06-07 2009-01-23 Janssen Pharmaceutica Nv Antagonistas del receptor de urotensina ii
EA017648B1 (ru) 2007-09-14 2013-02-28 Орто-Макнейл-Янссен Фармасьютикалз, Инк. 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2н,1'н-[1,4']бипириди-нил-2'-оны
ES2379762T3 (es) * 2008-08-02 2012-05-03 Janssen Pharmaceutica N.V. Antagonistas del receptor de la urotensina II
JP5547194B2 (ja) 2008-09-02 2014-07-09 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
MY160002A (en) 2009-02-10 2017-02-15 Celgene Corp Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
HRP20131122T1 (hr) 2009-05-12 2013-12-20 Janssen Pharmaceuticals, Inc. Derivati 1,2,4-triazolo[4,3-a] piridina i njihova uporaba u lijeäśenju ili prevenciji neuroloških i psihijatrijskih poremeä†aja
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439015B (zh) 2009-05-12 2015-05-13 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
WO2011127019A2 (en) 2010-04-07 2011-10-13 Celgene Corporation Methods for treating respiratory viral infection
JP2013531499A (ja) 2010-06-15 2013-08-08 セルジーン コーポレイション 乾癬の治療のためのバイオマーカー
EP2661435B1 (de) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazol[4,3-a]pyridinderivate und ihre verwendung als positive allosterische mglur2-rezeptormodulatoren
JP5852664B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
CN102993153B (zh) * 2012-12-29 2015-05-13 吉首大学 异黄酮-n-甲基氧肟酸类尿素酶抑制剂及其合成和用途
CN102976974B (zh) * 2012-12-29 2015-01-21 吉首大学 苯基苄基丙酰-n-甲基氧肟酸类尿素酶抑制剂及其合成和用途
CN102993152B (zh) * 2012-12-29 2015-04-01 吉首大学 尿素酶抑制剂异黄酮氧肟酸化合物及其合成和用途
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
ME03518B (de) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinationen mit positiven allosterischen modulatoren von metabotropem glutamatergen rezeptor vom subtyp 2 und deren verwendung
PL3096790T3 (pl) 2014-01-21 2020-01-31 Janssen Pharmaceutica, N.V. Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie
EP3142663A1 (de) 2014-05-16 2017-03-22 Celgene Corporation Zusammensetzungen und verfahren zur behandlung von arteriosklerotischen herz-kreislauf-erkrankungen mit pde4-modulatoren
WO2015200177A1 (en) 2014-06-23 2015-12-30 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
US10011611B2 (en) 2015-08-14 2018-07-03 Reaction Biology Corp. Histone deacetylase inhibitors and methods for use thereof
WO2017070291A1 (en) 2015-10-21 2017-04-27 Celgene Corporation Pde4 modulators for treating and preventing immune reconstitution inflammatory syndrome (iris)
KR102445637B1 (ko) * 2017-11-28 2022-09-22 솔브레인 주식회사 레벨링제 및 이를 포함하는 전기도금 조성물
CN110386893B (zh) * 2018-04-17 2025-07-11 天津合美医药科技有限公司 异吲哚衍生物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4077998A (en) * 1975-10-28 1978-03-07 Morton-Norwich Products, Inc. Phthaloyl amino acid hydroxamic acids
US4173652A (en) 1976-12-18 1979-11-06 Akzona Incorporated Pharmaceutical hydroxamic acid compositions and uses thereof
SU717044A1 (ru) * 1978-03-06 1980-02-25 Пермский государственный фармацевтический институт Амиды -фталимидомасл ной кислоты,про вл ющие противосудорожную активность
US4820828A (en) 1987-03-04 1989-04-11 Ortho Pharmaceutical Corporation Cinnamohydroxamic acids
US5605914A (en) * 1993-07-02 1997-02-25 Celgene Corporation Imides
US5463063A (en) * 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
EP0850215B1 (de) 1995-07-26 2000-10-18 Pfizer Inc. N-aroyl-glycin-hydroxamsäure-derivate und verwandte verbindungen
US5728844A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
ES2196592T3 (es) 1997-07-31 2003-12-16 Celgene Corp Acidos alcanohidroxamicos sustituidos y metodo para reducir el nivel de tnf-alfa.

Also Published As

Publication number Publication date
KR100716475B1 (ko) 2007-05-10
JP2001511448A (ja) 2001-08-14
DE69813876T2 (de) 2004-01-29
NO996529L (no) 2000-03-28
CZ299873B6 (cs) 2008-12-17
EP1035848B1 (de) 2003-04-23
US20040006096A1 (en) 2004-01-08
CN1265590A (zh) 2000-09-06
CZ2000256A3 (cs) 2000-06-14
ES2196592T3 (es) 2003-12-16
WO1999006041A1 (en) 1999-02-11
NZ502379A (en) 2002-10-25
FI20000061L (fi) 2000-03-02
US6656964B2 (en) 2003-12-02
NO315043B1 (no) 2003-06-30
RU2199530C2 (ru) 2003-02-27
KR20010022429A (ko) 2001-03-15
DE69813876D1 (de) 2003-05-28
BR9815895A (pt) 2001-01-16
EP1035848A4 (de) 2001-05-23
US7091356B2 (en) 2006-08-15
EP1035848A1 (de) 2000-09-20
FI119841B (fi) 2009-04-15
AU8674198A (en) 1999-02-22
NO996529D0 (no) 1999-12-28
TR200000221T2 (tr) 2000-09-21
US20010049371A1 (en) 2001-12-06
AU737008B2 (en) 2001-08-09
CA2295295A1 (en) 1999-02-11
PT1035848E (pt) 2003-09-30
HUP0003761A2 (en) 2001-03-28
US6214857B1 (en) 2001-04-10
HUP0003761A3 (en) 2001-04-28

Similar Documents

Publication Publication Date Title
DE69813876T2 (de) Susstituierte alkanhydroxamisaeure und verfahren zur verminderung des tnf-alphaspiegels
PT1038039E (pt) Inoculante de ferro fundido e metedo para producao do inoculante de ferro fundido
DE69936873D1 (de) Verfahren und System zur Vemittlung von Sitzungen und Anrufen
DE69837726D1 (de) Verfahren und Vorrichtung zur nahtlosen Wiedergabe von Videoprogrammen
TW200727895A (en) Substituted acylhydroxamic acids and a method of reducing TNF-α levels
DE69835020D1 (de) Plasmabrenner und verwendungsverfahren dieses plasmabrenners
IS4928A (is) Fosfín tengdir tálmar af grindar málmpróteösum
DE69730473D1 (de) System zur Kodierung und Übertragung von Sprachsignalen
ID19293A (id) Proses pembuatan dan penggunaan aditif semen
DE19780309D2 (de) Verfahren zur Regelung eines Aggregats und Frequenzumrichter
DE59808633D1 (de) Verfahren zur aktiven dämpfung einer verbrennungsschwingung und anwendung des verfarens
ATE420432T1 (de) Verfahren und vorrichtung zur prädiktiven quantisierung von stimmhaften sprachsignalen
DE69630331D1 (de) Verfahren zur gesicherten Sitzungsschlüsselerzeugung und zur Authentifizierung
NO973035D0 (no) Hydroksaminsyre-holdige inhibitorer for matriks-metallproteaser
NO940819D0 (no) Inokuleringsmiddel for stöpejern og fremgangsmåte for fremstilling av inokuleringsmiddel
DE69710479D1 (de) Organomineralgel zur dekontamination von oberflächen
ID26400A (id) Alat dan metode pengoreksi kesalahan bentuk luar
ID22650A (id) Penggunaan penghambat-penghambat lipase usus lambung
ATE294187T1 (de) Inhibitoren von picornavirus 3c protease und verfahren zur herstellung und verwendung
FI964174L (fi) Menetelmät tehokkaisen yhdistelmä-DNA-seriiniproteaasi-inhibiittoreiden tuottamiseksi ja näiden inhibiittorien käyttöjä
ID19459A (id) Metoda dan peralatn penyampaian pesan
DE69813022D1 (de) Injektor zur behandlung von metallschmelzen mit gasen
DE59509471D1 (de) Verfahren zur regelung des lastannahme- und beschleunigungsverhaltens von aufgeladenen brennkraftmaschinen
DE69828735D1 (de) Vorrichtung und System zur Stimmwiedergabe
BR9200615A (pt) Ferro fundido nodular e processo de obtencao de ferro fundido nodular

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1035848

Country of ref document: EP

REN Ceased due to non-payment of the annual fee